Piasky: Dosage Form, Projected Sales, NCE-1 Date | Crovalimab-Akkz

Piasky

Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Crovalimab-Akkz
Innovator :

GENENTECH
Approval Date :

20-Jun-24
Data Exclusivity Expiry :

20-Jun-28
Market Exclusivity Expiry :

20-Jun-36
Dosage Form :

Intravenous Infusion
Strength :

340mg/2ml
Therapeutic Category :

Immunomodulators
Revenue ($M) :

18

Year-wise Projected Sales ($M) :

2025 :

110
2026 :

212
2027 :

302
2028 :

379
2029 :

455
2030 :

526
2031 :

592

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Piasky

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?